NASDAQ:HOTH
Hoth Therapeutics Inc. Stock News
$1.18
-0.0100 (-0.84%)
At Close: May 17, 2024
Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne
08:15am, Tuesday, 13'th Jul 2021
NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive results
NEW YORK, June 28, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the safety results in Cohort 1 of its first in human cli
Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ
02:31pm, Monday, 07'th Jun 2021
NEW YORK, June 7, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement
Hoth Therapeutics Unveils Preclinical Results of HT-KIT Therapeutic Program
12:32pm, Thursday, 03'rd Jun 2021
Hoth Therapeutics Inc (NASDAQ: HOTH) has reported results from a preclinical trial of HT-KIT, a new molecular entity under development to treat mast cell-derived cancers and anaphylaxis. HT-KIT is
Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic
08:01am, Thursday, 03'rd Jun 2021
NEW YORK, June 3, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will share positive results from a preclinical t
Hoth Therapeutics Plans Shareholder Presentation on HT-KIT Therapeutic's Preclinical Results for Rare Cancers
08:05am, Tuesday, 01'st Jun 2021
NEW YORK, June 1, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today plans to host a virtual information session on its pipel
Hoth Therapeutics Announces Participation at the American Society of Clinical Oncology (ASCO) Annual Meeting
08:01am, Monday, 24'th May 2021
NEW YORK, May 24, 2021 /PRNewswire/ -- Hoth Therapeutics , Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will be an exhibitor at the American Society of
HOTH Therapeutics (NASDAQ: HOTH): Developing Life-Changing Drugs for Rare Cancers and Diseases
10:41am, Tuesday, 18'th May 2021
HOTH Therapeutics was one of the sponsors for the Benzinga Biotech Small Cap Conference that took place on March 24-25, 2021. The information contained in this article in no way represents investment
Hoth Therapeutics Provides Shareholder Update on Novel Endocannabinoid Therapeutic for Cutaneous Lupus Erythematosus
08:28am, Thursday, 13'th May 2021
NEW YORK, May 13, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today it plans to host a virtual information session on its p
Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers
09:13am, Monday, 03'rd May 2021
NEW YORK, May 3, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it intends to pursue development of its HT-KIT mR
Hoth Therapeutics' mRNA Frame Shifting Therapeutic Inhibits Tumor Growth, Animal Study Shows
02:07pm, Tuesday, 20'th Apr 2021
Hoth Therapeutics Inc (NASDAQ: HOTH) has reported that its novel anti-cancer therapeutic demonstrated positive results in humanized mast-cell neoplasm animal models for aggressive, mast cell-deriv
Hoth Therapeutics Announces its mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell-Derived Cancers
09:06am, Tuesday, 20'th Apr 2021
NEW YORK, April 20, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, announced that its novel anti-cancer therapeutic exhibit
Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial
09:15am, Monday, 12'th Apr 2021
NEW YORK, April 12, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully complet
NEW YORK, April 6, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced that it has engaged Worldwide Clinical Trials ("Worldwide"), a
NEW YORK, April 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that the Brazilian Patent Office has issue
